AAN - American Academy of Neurology

April 18-22
Chicago, IL

Tardive Dyskinesia

Real-World Use of Deutetrabenazine Reduces Tardive Dyskinesia Severity and Improves Quality of Life: Patient-Reported Outcomes in the IMPACT-TD Study

 

Authors:
Stacy Finkbeiner, Martijn Konings, Mark Henegar, Diana Klakotskaia, Daisy Yu, Richard Jackson

Download the poster

Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use

 

Authors:
Rakesh Jain, Martijn Konings, Maurice T. Driessen, Sameer Kotak, Pooja Gandhi

Download the poster